{
    "root": "97a53650-f9e2-432d-a5bc-c2629021e056",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Wakix",
    "value": "20250513",
    "ingredients": [
        {
            "name": "PITOLISANT HYDROCHLORIDE",
            "code": "YV33CH63HI",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134709"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30563"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "indications": {
        "text": "wakix indicated : treatment excessive daytime sleepiness ( eds ) cataplexy adult patients narcolepsy . treatment excessive daytime sleepiness ( eds ) pediatric patients 6 years age older narcolepsy .",
        "doid_entities": [
            {
                "text": "narcolepsy (DOID:8986)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_8986"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "full prescribing information complete instructions ( 2.1 , 2.2 ) administer orally daily morning upon wakening ( 2.1 , 2.2 ) recommendations : adults : eds cataplexy ( 2.1 ) week 1 initiate 8.9 mg daily week 2 increase 17.8 mg daily week 3 may increase maximum recommended 35.6 mg daily pediatric patients ( 6 years older ) : eds ( 2.2 ) week 1 initiate 4.45 mg daily week 2 increase 8.9 mg daily week 3 increase 17.8 mg daily , maximum recommended patients weighing < 40 kg week 4 patients weighing \u226540 kg , may increase maximum recommended 35.6 mg daily hepatic impairment ( 2.3 , 8.6 , 12.3 ) : moderate hepatic impairment ( child-pugh class b ) : adults : initial 8.9 mg daily . titrate maximum 17.8 mg daily 14 days pediatric patients : initial 4.45 mg daily . titrate 8.9 mg daily 14 days ; patients weighing \u226540 kg , may increase 17.8 mg daily another 14 days renal impairment ( egfr less 60 ml/minute/1.73 2 ) ( 2.4 , 8.7 , 12.3 ) : adults : initial 8.9 mg daily . titrate maximum 17.8 mg daily 7 days pediatric patients : initial 4.45 mg daily . titrate 8.9 mg daily 7 days ; patients weighing \u226540 kg , may increase 17.8 mg daily another 7 days end-stage renal disease ( esrd ) : recommended poor metabolizers cyp2d6 ( 2.6 ) : adults : maximum recommended 17.8 mg daily pediatric patients : maximum recommended 8.9 mg daily patients weighing < 40 kg 17.8 mg patients weighing \u226540 kg",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "wakix ( pitolisant ) tablets available : 4.45 mg : white , round , biconvex film-coated tablet , 3.7 mm diameter , marked \u201c \u201d one side plain side . ndc 72028-045-03 \u2013 bottles 30 17.8 mg : white , round , biconvex film-coated tablet , 7.5 mm diameter , marked \u201c h \u201d one side plain side . ndc 72028-178-03 \u2013 bottles 30",
    "adverseReactions": "wakix contraindicated patients : known hypersensitivity pitolisant component formulation . anaphylaxis reported patients treated wakix [ ( 6.2 ) ] . severe hepatic impairment . wakix extensively metabolized liver significant increase wakix exposure patients moderate hepatic impairment [ ( 8.6 ) ] .",
    "indications_original": "WAKIX is indicated for the:\n                  \n                     treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy.\n                     \n                        treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.",
    "contraindications_original": "See Full Prescribing Information for complete dosage instructions ( 2.1 , 2.2 ) Administer orally once daily in the morning upon wakening ( 2.1 , 2.2 ) Dosage Recommendations: Adults: EDS or Cataplexy ( 2.1 ) Week 1 Initiate with a dosage of 8.9 mg once daily Week 2 Increase dosage to 17.8 mg once daily Week 3 May increase to the maximum recommended dosage of 35.6 mg once daily Pediatric Patients (6 years and older): EDS ( 2.2 ) Week 1 Initiate with a dosage of 4.45 mg once daily Week 2 Increase dosage to 8.9 mg once daily Week 3 Increase dosage to 17.8 mg once daily, the maximum recommended dosage for patients weighing <40 kg Week 4 For patients weighing \u226540 kg, may increase to the maximum recommended dosage of 35.6 mg once daily Hepatic impairment ( 2.3 , 8.6 , 12.3 ): Moderate hepatic impairment (Child-Pugh Class B): Adults: Initial dosage is 8.9 mg once daily. Titrate to a maximum dosage of 17.8 mg once daily after 14 days Pediatric Patients: Initial dosage is 4.45 mg once daily. Titrate to 8.9 mg once daily after 14 days; for patients weighing \u226540 kg, may increase to 17.8 mg once daily after another 14 days Renal impairment (eGFR less than 60 mL/minute/1.73 m 2 ) ( 2.4 , 8.7 , 12.3 ): Adults: Initial dosage is 8.9 mg once daily. Titrate to a maximum dosage of 17.8 mg once daily after 7 days Pediatric Patients: Initial dosage is 4.45 mg once daily. Titrate to 8.9 mg once daily after 7 days; for patients weighing \u226540 kg, may increase to 17.8 mg once daily after another 7 days End-stage renal disease (ESRD): Not recommended Poor Metabolizers of CYP2D6 ( 2.6 ): Adults: Maximum recommended dosage is 17.8 mg once daily Pediatric Patients: Maximum recommended dosage is 8.9 mg once daily for patients weighing <40 kg and 17.8 mg for patients weighing \u226540 kg",
    "warningsAndPrecautions_original": "WAKIX (pitolisant) tablets are available as:\n                        4.45 mg: white, round, biconvex film-coated tablet, 3.7 mm diameter, marked with \u201cS\u201d on one side and plain on the other side.\n                        NDC 72028-045-03 \u2013 Bottles of 30\n                        17.8 mg: white, round, biconvex film-coated tablet, 7.5 mm diameter, marked with \u201cH\u201d on one side and plain on the other side.\n                        NDC 72028-178-03 \u2013 Bottles of 30",
    "adverseReactions_original": "WAKIX is contraindicated in patients with:\n                  \n                     known hypersensitivity to pitolisant or any component of the formulation. Anaphylaxis has been reported in patients treated with WAKIX [see Adverse Reactions (6.2)].\n                     severe hepatic impairment. WAKIX is extensively metabolized by the liver and there is a significant increase in WAKIX exposure in patients with moderate hepatic impairment [see Use in Specific Populations (8.6)].",
    "drug": [
        {
            "name": "Wakix",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_134709"
        }
    ]
}